Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system

Antiviral Therapy

Volumn 16, Issue 2, 2011, Pages 207-218

  Walczak, Mateusz ^a   Regts, Joke ^a   Van Oosterhout, Antoon J M ^a   Boon, Louis ^b   Wilschut, Jan ^a   Nijman, Hans W ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BIOCEROS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA VIRUS VECTOR; E6 E7 PROTEIN; FOLATE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOTHERAPY; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPLICON; SEMLIKI FOREST ALPHAVIRUS; T CELL DEPLETION; TUMOR GROWTH; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT;

ALPHAVIRUS; ANIMALS; CANCER VACCINES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNIZATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; RECOMBINATION, GENETIC; REPRESSOR PROTEINS; SEMLIKI FOREST VIRUS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; VACCINATION;

EID: 79953177481     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1751     Document Type: Article

References (55)

1. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-3633. (Pubitemid 43121851)
2. Delluc S, Hachem P, Rusakiewicz S, et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother 2009; 58:1669-1677.
3. Imai H, Saio M, Nonaka K, et al. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007; 98:416-423. (Pubitemid 46195615)
4. Jacob JB, Kong YC, Nalbantoglu I, Snower DP, Wei WZ. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol 2009; 182:5873-5881.
5. Kottke T, Pulido J, Thompson J, et al. Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res 2009; 69:7767-7774.
6. Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 2005; 11:4533-4544. (Pubitemid 40825644)
7. + T regulatory cell function implicated in enhanced immune response by lowdose cyclophosphamide. Blood 2005; 105:2862-2868.
8. Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009; 69:4309-4318.
9. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004; 199:1401-1408.
10. Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847-8855. (Pubitemid 47437461)
11. + T regulatory cells. Clin Exp Immunol 2007; 149:226-234.
12. Maksimow M, Miiluniemi M, Marttila-Ichihara F, Jalkanen S, Hanninen A. Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. Blood 2006; 108:1298-1305. (Pubitemid 44232028)
13. Silver PB, Agarwal RK, Su SB, et al. Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J Immunol 2007; 179:5146-5158.
14. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107:628-636. (Pubitemid 43076387)
15. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20:241-246.
16. Visser J, Nijman HW, Hoogenboom BN, et al. Frequencies and role of regulatory T cells in patients with (pre) malignant cervical neoplasia. Clin Exp Immunol 2007; 150:199-209. (Pubitemid 47609556)
17. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19:217-223. (Pubitemid 46356965)
18. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9:606-612. (Pubitemid 36182591)
19. + regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009; 10:689-695.
20. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007; 8:191-197. (Pubitemid 46152650)
21. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841-855.
22. high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006; 108:2655-2661.
23. + regulatory T cells that secrete TGF[beta] and IL-10 are preferentially induced by a vaccine vector. J Immunother 2004; 27:339-346.
24. Daemen T, Regts J, Holtrop M, Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther 2002; 9:85-94. (Pubitemid 34189523)
25. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991; 9:1356-1361.
26. Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B, Wilschut J. Eradication of established HPV16- transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 2003; 21:1082-1088. (Pubitemid 36139938)
27. Daemen T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A, Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 2004; 9:733-742. (Pubitemid 39434337)
28. Riezebos-Brilman A, Regts J, Freyschmidt EJ, Dontje B, Wilschut J, Daemen T. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 2005; 12:1410-1414. (Pubitemid 43090391)
29. Riezebos-Brilman A, Walczak M, Regts J, et al. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther 2007; 14:1695-1704. (Pubitemid 350238446)
30. + regulatory T cells. Curr Opin Immunol 2004; 16:203-208.
31. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-562.
32. + regulatory T cells. Nat Immunol 2003; 4:330-336.
33. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061. (Pubitemid 36222930)
34. + T regulatory cells. Nat Immunol 2003; 4:337-342.
35. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-787. (Pubitemid 351707693)
36. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007; 8:457-462. (Pubitemid 46605910)
37. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112:610-618.
38. Powell DJ, Jr., Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007; 179:4919-4928.
39. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174:99-106.
40. + regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol 2007; 178:4136-4146.
41. Kohm AP, McMahon JS, Podojil JR, et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 2006; 176:3301-3305. (Pubitemid 43363974)
42. Curtin JF, Candolfi M, Fakhouri TM, et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE 2008; 3:e1983.
43. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007; 27:145-159. (Pubitemid 47089022)
44. Chen G, Li N, Zang YC, et al. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum 2007; 56:453-463.
45. Cabrera A, Saez D, Cespedes S, Andrews E, Onate A. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology 2009; 214:467-474.
46. Cassetti MC, McElhiney SP, Shahabi V, et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004; 22:520-527. (Pubitemid 37510284)
47. Miller A, Center RJ, Stambas J, et al. Sindbis virus vectors elicit hemagglutinin-specific humoral and cellular immune responses and offer a dose-sparing strategy for vaccination. Vaccine 2008; 26:5641-5648.
48. Riezebos-Brilman A, de Mare A, Bungener L, Huckriede A, Wilschut J, Daemen T. Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol 2006; 35:233-243. (Pubitemid 43188967)
49. Zheng M, Jin NY, Liu Q, et al. Immunogenicity and protective efficacy of Semliki Forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins. Virology 2009; 391:33-43.
50. Sutmuller RP, den Brok MH, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116:485-494. (Pubitemid 43228366)
51. + regulatory T cells allows for their purification from expansion cultures. Blood 2009; 113:5125-5133.
52. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333:167-179.
53. Teng MW, Swann JB, von Scheidt B, et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 2010; 70:2665-2674.
54. Tuve S, Chen BM, Liu Y, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007; 67:5929-5939. (Pubitemid 46985029)
55. + T regulatory cells. Vaccine 2009; 27:684-689.